Optimal primary surgical treatment for advanced epithelial ovarian cancer
- PMID: 21833960
- PMCID: PMC6457688
- DOI: 10.1002/14651858.CD007565.pub2
Optimal primary surgical treatment for advanced epithelial ovarian cancer
Abstract
Background: Ovarian cancer is the sixth most common cancer among women. In addition to diagnosis and staging, primary surgery is performed to achieve optimal cytoreduction (surgical efforts aimed at removing the bulk of the tumour) as the amount of residual tumour is one of the most important prognostic factors for survival of women with epithelial ovarian cancer. An optimal outcome of cytoreductive surgery remains a subject of controversy to many practising gynae-oncologists. The Gynaecologic Oncology group (GOG) currently defines 'optimal' as having residual tumour nodules each measuring 1 cm or less in maximum diameter, with complete cytoreduction (microscopic disease) being the ideal surgical outcome. Although the size of residual tumour masses after surgery has been shown to be an important prognostic factor for advanced ovarian cancer, it is unclear whether it is the surgical procedure that is directly responsible for the superior outcome that is associated with less residual disease.
Objectives: To evaluate the effectiveness and safety of optimal primary cytoreductive surgery for women with surgically staged advanced epithelial ovarian cancer (stages III and IV).To assess the impact of various residual tumour sizes, over a range between zero and 2 cm, on overall survival.
Search strategy: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 3) and the Cochrane Gynaecological Cancer Review Group Trials Register, MEDLINE and EMBASE (up to August 2010). We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field.
Selection criteria: Retrospective data on residual disease from randomised controlled trials (RCTs) or prospective and retrospective observational studies which included a multivariate analysis of 100 or more adult women with surgically staged advanced epithelial ovarian cancer and who underwent primary cytoreductive surgery followed by adjuvant platinum-based chemotherapy. We only included studies that defined optimal cytoreduction as surgery leading to residual tumours with a maximum diameter of any threshold up to 2 cm.
Data collection and analysis: Two review authors independently abstracted data and assessed risk of bias. Where possible, the data were synthesised in a meta-analysis.
Main results: There were no RCTs or prospective non-RCTs identified that were designed to evaluate the effectiveness of surgery when performed as a primary procedure in advanced stage ovarian cancer.We found 11 retrospective studies that included a multivariate analysis that met our inclusion criteria. Analyses showed the prognostic importance of complete cytoreduction, where the residual disease was microscopic that is no visible disease, as overall (OS) and progression-free survival (PFS) were significantly prolonged in these groups of women. PFS was not reported in all of the studies but was sufficiently documented to allow firm conclusions to be drawn.When we compared suboptimal (> 1 cm) versus optimal (< 1 cm) cytoreduction the survival estimates were attenuated but remained statistically significant in favour of the lower volume disease group There was no significant difference in OS and only a borderline difference in PFS when residual disease of > 2 cm and < 2 cm were compared (hazard ratio (HR) 1.65, 95% CI 0.82 to 3.31; and HR 1.27, 95% CI 1.00 to 1.61, P = 0.05 for OS and PFS respectively).There was a high risk of bias due to the retrospective nature of these studies where, despite statistical adjustment for important prognostic factors, selection bias was still likely to be of particular concern.Adverse events, quality of life (QoL) and cost-effectiveness were not reported by treatment arm or to a satisfactory level in any of the studies.
Authors' conclusions: During primary surgery for advanced stage epithelial ovarian cancer all attempts should be made to achieve complete cytoreduction. When this is not achievable, the surgical goal should be optimal (< 1 cm) residual disease. Due to the high risk of bias in the current evidence, randomised controlled trials should be performed to determine whether it is the surgical intervention or patient-related and disease-related factors that are associated with the improved survival in these groups of women. The findings of this review that women with residual disease < 1 cm still do better than women with residual disease > 1 cm should prompt the surgical community to retain this category and consider re-defining it as 'near optimal' cytoreduction, reserving the term 'suboptimal' cytoreduction to cases where the residual disease is > 1 cm (optimal/near optimal/suboptimal instead of complete/optimal/suboptimal).
Conflict of interest statement
None
Figures


















Update of
- doi: 10.1002/14651858.CD007565
Similar articles
-
Surgical cytoreduction for recurrent epithelial ovarian cancer.Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD008765. doi: 10.1002/14651858.CD008765.pub3. Cochrane Database Syst Rev. 2013. PMID: 23450588 Free PMC article. Review.
-
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.Cochrane Database Syst Rev. 2011 Apr 13;(4):CD007697. doi: 10.1002/14651858.CD007697.pub2. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2022 Aug 30;8:CD007697. doi: 10.1002/14651858.CD007697.pub3. PMID: 21491400 Free PMC article. Updated. Review.
-
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.Cochrane Database Syst Rev. 2022 Aug 30;8(8):CD007697. doi: 10.1002/14651858.CD007697.pub3. Cochrane Database Syst Rev. 2022. PMID: 36041232 Free PMC article. Review.
-
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.Cochrane Database Syst Rev. 2021 Jul 30;7(7):CD005343. doi: 10.1002/14651858.CD005343.pub6. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2025 Feb 10;2:CD005343. doi: 10.1002/14651858.CD005343.pub7. PMID: 34328210 Free PMC article. Updated.
-
Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.Cochrane Database Syst Rev. 2013 Jun 6;2013(6):CD009620. doi: 10.1002/14651858.CD009620.pub2. Cochrane Database Syst Rev. 2013. PMID: 23740789 Free PMC article. Review.
Cited by
-
Disparities in treatment modalities and survival among older patients with high-grade serous ovarian cancer.BMC Womens Health. 2024 Feb 7;24(1):100. doi: 10.1186/s12905-024-02938-y. BMC Womens Health. 2024. PMID: 38326784 Free PMC article.
-
When is it safe to omit surgery in primary peritoneal cancer with small volume disease?Curr Oncol Rep. 2015 Aug;17(8):36. doi: 10.1007/s11912-015-0463-z. Curr Oncol Rep. 2015. PMID: 26045131 Review.
-
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol. 2016 Oct 1;34(28):3460-73. doi: 10.1200/JCO.2016.68.6907. Epub 2016 Aug 8. J Clin Oncol. 2016. PMID: 27502591 Free PMC article.
-
Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?Gynecol Oncol. 2018 Oct;151(1):24-31. doi: 10.1016/j.ygyno.2018.08.014. Epub 2018 Aug 17. Gynecol Oncol. 2018. PMID: 30126704 Free PMC article.
-
Role of laparoscopy in initial tumour staging in advanced epithelial ovarian cancer: A systematic review.Pleura Peritoneum. 2018 Mar 29;3(1):20180106. doi: 10.1515/pp-2018-0106. eCollection 2018 Mar 1. Pleura Peritoneum. 2018. PMID: 30911654 Free PMC article. Review.
References
References to studies included in this review
Akahira 2001 {published data only}
-
- Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology 2001;81(3):398‐403. - PubMed
Aletti 2006 {published data only}
-
- Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced‐stage ovarian cancer. Obstetrics and Gynecology 2006;107:77–85. - PubMed
-
- Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short‐term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology 2007;197(6):1‐7. - PubMed
-
- Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology 2006;100(2):283‐7. - PubMed
-
- Aletti GD, Podratz KC, Jones MB, Cliby WA. Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Journal of the American College of Surgeons 2006;203(4):521‐6. - PubMed
Chan 2003 {published data only}
-
- Chan JK, Loizzi V, Lin YG, Osann K, Brewster WR, DiSaia PJ. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: What prognostic factors are important?. Obstetrics and Gynecology 2003;102(1):156‐61. - PubMed
Chi 2001 {published data only}
-
- Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecologic Oncology 2001;82(3):532‐7. - PubMed
Chi 2006 {published data only}
-
- Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu‐Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecologic Oncology 2006;103:559–64. - PubMed
-
- Eisenhauer EL, Abu‐Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS. The effect of maximal surgical cytoreduction on sensitivity to platinum‐taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology 2008;108(2):276‐81. - PubMed
Eisenkop 2003 {published data only}
-
- Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecologic Oncology 1998;69(2):103‐8. - PubMed
-
- Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology 2003;90(2):390‐6. - PubMed
McGuire 1995 {published data only}
-
- Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology 1994;170(4):974‐80. - PubMed
-
- McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, et al. Assessment of dose‐intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 1995;13:1589‐99. - PubMed
Salani 2007 {published data only}
-
- Salani R, Zahurak ML, Santillan A, Giuntoli RL, Bristow RE. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: A case‐control study. Gynecologic Oncology 2007;107(3):495‐9. - PubMed
Van Geene 1996 {published data only}
-
- Geene P, Varma R, Dunn J, Chan KK, Luesley DM. The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer 1996;6(3):219‐24.
Winter 2007 {published data only}
-
- Armstrong DK, Bundy BW, LariHuang HQ, Baergen RL, Shashikant Copeland LJ, Walker JL, Burger RA, the Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine 2006;354(1):34‐43. - PubMed
-
- Markman M, Bundy BM, Alberts DS, Fowler JM, Clark‐Pearson DL, Carson LF, et al. Phase III Trial of Standard‐Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High‐Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small‐Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2001;19(4):1001‐07. - PubMed
-
- McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer. New England Journal of Medicine 1996;334(1):1‐6. - PubMed
-
- Muggia FM, Braly PS, Brady MF, Sutton GN, Theodore HL, Samuel LA, Ronald D.Kucera, Paul R.Small, James M. Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 2000;18(1):106‐115. - PubMed
-
- Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke‐Pearson DB, Robert AM, et al. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 2003;21(17):3194‐3200. - PubMed
Winter 2008 {published data only}
-
- McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer. New England Journal of Medicine 1996;334(1):1‐6. - PubMed
-
- Muggia FM, Braly PS, Brady MF, Sutton GN, Theodore HL, Samuel LA, et al. Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 2000;18(1):106‐115. - PubMed
-
- Rose PG, Nerenstone S, Brady MF, Clarke‐Pearson D, Olt G, Rubin SC, et al. Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma. New England Journal of Medicine 2004;351(24):2489‐97. - PubMed
-
- Spriggs DR, Brady MF, Vaccarello L, Clarke‐Pearson DL, Burger RA, Mannel R, et al. Phase III randomized trial of intravenous cisplatin plus a 24‐ or 96‐hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.. Journal of Clinical Oncology 2007;25(28):4466‐71. - PubMed
-
- Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2008;26(1):83‐9. - PubMed
References to studies excluded from this review
Alberts 1993 {published data only}
-
- Alberts DS, Dahlberg S, Green SJ, Garcia D, Hannigan EV, O'Toole R, et al. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin‐cyclophosphamide versus carboplatin‐cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study.. Cancer 1993;71(2 Suppl):618‐627. - PubMed
Alberts 1996 {published data only}
-
- Alberts DS, Liu PY, Hannigan EEV, O'Toole RW, Stephen DY, James AF, et al. Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer. New England Journal of Medicine 1996;335(26):1950‐55. - PubMed
Alphs 2006 {published data only}
-
- Alphs HH, Zahurak ML, Bristow RE, Diaz‐Montes TP. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecologic Oncology 2006;103(3):1048‐53. - PubMed
Andersen Soegaard 2005 {published data only}
-
- Soegaard Andersen E, Knudsen A, Svarrer T, Lund B, Nielsen K, Grove A, et al. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Gynecologic Oncology 2005;99(3):552‐6. - PubMed
Bailey 2006 {published data only}
-
- Bailey J, Murdoch J, Anderson R, Weeks J, Foy C. Stage III and IV ovarian cancer in the South West of England: five‐year outcome analysis for cases treated in 1998. International Journal of Gynecological Cancer 2006;1:25‐29. - PubMed
Baker 1994 {published data only}
-
- Baker TR, Piver MS, Hempling RE. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer 1994;74(2):656‐63. - PubMed
Barda 2004 {published data only}
-
- Barda G, Menczer J, Chetrit A, Lubin F, Beck D, Piura B, et al. Comparison between primary peritoneal and epithelial ovarian carcinoma: A population‐based study. American Journal of Obstetrics and Gynecology 2004;190(4):1039‐45. - PubMed
Benedetti‐Panici 1996 {published data only}
-
- Benedetti‐Panici P, Maneschi F, Scambia G, Cutillo G, Greggi S, Mancuso S. The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma. Obstetrics & Gynecology 1996;87(4):532‐38. - PubMed
Bertelsen 1990 {published data only}
-
- Bertelsen K. Tumor reduction surgery and long‐term survival in advanced ovarian cancer: a DACOVA study. Gynecologic Oncology 1990;38(2):203‐9. - PubMed
Bertelsen 1993 {published data only}
-
- Bertelsen K, Jakobsen A, Strøyer J, Nielsen K, Sandberg E, Andersen JE, et al. A Prospective Randomized Comparison of 6 and 12 Cycles of Cyclophosphamide, Adriamycin, and Cisplatin in Advanced Epithelial Ovarian Cancer: A Danish Ovarian Study Group Trial (DACOVA). Gynecologic Oncology 1993;49:30‐36. - PubMed
Bonnefoi 1999 {published data only}
-
- Bonnefoi H, A'Hern RP, Fisher C, Macfarlane V, Barton D, Blake P, et al. Natural history of stage IV epithelial ovarian cancer.[see comment]. Journal of Clinical Oncology 1999;17(3):767‐75. - PubMed
Brinkhuis 1996a {published data only}
-
- Brinkhuis M, Baak J P A, Diest P J, Lund B, Wils J. In Dutch and Danish patients with FIGO III ovarian carcinoma, geographic survival differences are associated with differences in quantitative pathologic features. International Journal of Gynecological Cancer 1996;6(2):108‐14.
Brinkhuis 1996b {published data only}
-
- Brinkhuis M, Lund B, Meijer GA, Baak JPA. Quantitative pathological variables as prognostic factors for overall survival in Danish patients with FIGO stage III ovarian cancer. International Journal of Gynecological Cancer 1996;6(3):168‐174.
Bristow 1999 {published data only}
-
- Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecologic Oncology 1999;72(3):278‐87. - PubMed
Cai 2007 {published data only}
-
- Cai HB, Zhou YF, Chen HZ, Hou HY. The Role of Bowel Surgery with Cytoreduction for Epithelial Ovarian Cancer. Clinical Oncology 2007;19(10):757‐762. - PubMed
Colozza 1997 {published data only}
-
- Colozza M, Mosconi AM, Gori S, Belsanti V, Basurto C, Angelis V, et al. Long‐term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide. American Journal of Clinical Oncology 1997;20(5):522‐26. - PubMed
Conte 1991 {published data only}
-
- Conte PF, Bruzzone M, Carnino F, Chiara S, Donadio M, Facchini V, et al. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III‐IV epithelial ovarian carcinoma. Journal of Clinical Oncology 1991;9(4):658‐63. - PubMed
Conte 1996 {published data only}
-
- Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A, et al. High‐dose versus low‐dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord‐Ovest. Journal of Clinical Oncology 1996;14(2):351‐56. - PubMed
Crawford 2005 {published data only}
-
- Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC‐1 trial. Journal of Clinical Oncology 2005;23(34):8802‐11. - PubMed
Creasman 1990 {published data only}
-
- Creasman WT, Omura GA, Brady MF, Yordan E, DiSaia PJ, Beecham J. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette‐Guerin in patients with suboptimal stage III and IV ovarian cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology 1990;39(3):239‐43. - PubMed
de Oliviera 1990 {published data only}
-
- Oliveira CF, Lacave AJ, Villani C, Wolff JP, Re F, Namer M. Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study.. European Journal of Gynaecologic Oncology 1990;11(5):323‐30. - PubMed
Del Campo 1994 {published data only}
-
- Del Campo, Jose M.Felip, EnriquetaRubio, DiegoVidal, RosoBermejo, BegoñaColomer, RamonZanon, Vicente. Long‐Term Survival in Advanced Ovarian Cancer after Cytoreduction and Chemotherapy Treatment. Gynecologic Oncology 1994;53(1):27‐32. - PubMed
di Re 1996 {published data only}
-
- Re F, Baiocchi G, Fontanelli R, Grosso G, Cobellis L, Raspagliesi F, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecologic Oncology 1996;62(3):360‐65. - PubMed
Gao 2001 {published data only}
-
- Gao J, Zheng A, Chen W, Peng Z, Cao Z. [A study of prognostic factors of stage IV epithelial ovarian cancer]. [Chinese]. Hua Hsi i Ko Ta Hsueh Hsueh Pao [Journal of West China University of Medical Sciences] 2001;32(2):309‐312. - PubMed
Geisler 2004 {published data only}
-
- Geisler JP, Tammela JE, Manahan KJ, Geisler HE, Miller GA, Zhou Z, et al. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow‐up. European Journal of Gynaecological Oncology 2004;25(2):165‐168. - PubMed
Gershenson 1989 {published data only}
-
- Gershenson DM, Wharton J, Taylor C, Stringer LJ, Edwards CA, Creighton L, et al. Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide. Gynecologic Oncology 1989;32(3):336‐341. - PubMed
Gershenson 1992 {published data only}
-
- Gershenson DM, Mitchell MF, Atkinson N, Elvio G, Kavanagh J, Burke M, et al. The effect of prolonged cisplatin‐based chemotherapy on progression‐free survival in patients with optimal epithelial ovarian cancer: "Maintenance" therapy reconsidered. Gynecologic Oncology 1992;47(1):7‐13. - PubMed
Gershenson 1995 {published data only}
-
- Gershenson DM, Morris M, Burke TW, Levenback C, Kavanagh JJ, Fromm GL. Combined Cisplatin and Carboplatin Chemotherapy for Treatment of Advanced Epithelial Ovarian Cancer. Gynecologic Oncology 1995;58(3):349‐355. - PubMed
Grem 1991 {published data only}
-
- Grem J, O'Dwyer P, Elson P, Simon N, Trump D, Frontiera M, et al. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced‐stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study. Journal of Clinical Oncology 1989;9(10):1793‐1800. - PubMed
Hainsworth 1990 {published data only}
-
- Hainsworth JD, Burnett LS, Jones HW 3rd, Grosh WW, Johnson DH, Greco FA. High‐dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Journal of Clinical Oncology 1990;8(3):502‐508. - PubMed
Hakes 1992 {published data only}
-
- Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecologic Oncology 1992;45(3):284‐289. - PubMed
Hamid 2002 {published data only}
-
- Hamid D, Rohr S, Baldauf JJ, Ritter J, Kurtz E, Dufour P, et al. Interest of intestinal resection for treatment of advanced ovarian carcinoma [Intérét des exéréses digestives dans le traitement des cancers écolués de l'ovaire]. Annales de Chirurgie 2002;127(1):40‐47. - PubMed
Hardy 1991 {published data only}
-
- Hardy JR, Wiltshaw E, Blake PR, Harper P, Slevin M, Perren TJ, et al. Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma. Annals of Oncology 1991;2(2):131‐136. - PubMed
Hoskins 1992 {published data only}
-
- Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence‐free interval and survival in small‐volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecologic Oncology 1992;47(2):159‐66. - PubMed
Hoskins 1996 {published data only}
-
- Hoskins PJ, Swenerton KD, Pike JA, McMurtrie EM, Lee N. "MECCA": A Developmental, Dose‐Intensive, Non‐Cross‐Resistant Platinum‐Based Chemotherapy for Advanced Ovarian Cancer. Gynecologic Oncology 1996;63(3):345‐351. - PubMed
Hoskins 1997 {published data only}
-
- Hoskins WJ, McGuire WP, Brady, MF, Kucera PR, Partridge EE, Look KY, et al. Combination paclitaxel (Taxol(R))‐cisplatin vs cyclophosphamide‐cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer. International Journal of Gynecological Cancer 1997;7:9‐13.
Itamochi 2002 {published data only}
-
- Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstetrics & Gynecology 2002;100(2):281‐287. - PubMed
Kaern 2005 {published data only}
-
- Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M, et al. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short‐ and long‐term survivors?. International Journal of Gynecological Cancer 2005;15(6):1014‐22. - PubMed
Kirmani 1994 {published data only}
-
- Kirmani S, Braly PS, McClay EF, Saltzstein SL, Plaxe SC, Kim S, et al. A Comparison of Intravenous versus Intraperitoneal Chemotherapy for the Initial Treatment of Ovarian Cancer. Gynecologic Oncology 1994;54(3):338‐344. - PubMed
Kristensen 1995 {published data only}
-
- Kristensen GB, Baekelandt M, Vergote IB, Trope C. A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. European Journal of Cancer 1995;31(11):1778‐80. - PubMed
Le 1997 {published data only}
-
- Le T, Krepart GV, Lotocki R J, Heywood MS. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?. Gynecologic Oncology 1997;67(2):208‐14. - PubMed
Lorusso 1998 {published data only}
-
- Lorusso V, Leone B, Vagno G, Manzione L, Palmeri S, Vallejo C. Combined Carboplatin plus Ifosfamide and Cisplatin in Patients with Advanced Ovarian Carcinoma. A Phase I‐II Study. Gynecologic Oncology 1998;68(2):172‐177. - PubMed
Malik 1998 {published data only}
-
- Malik IM, Khan ZK, Khan WA, Hussain M, Moid I, Rizvi J. Continuous infusion of ifosfamide and cisplatin as first‐line therapy of patients with suboptimally debulked stage III–IV epithelial ovarian cancer. International Journal of Gynecological Cancer 1998;8(2):138‐143.
Marchetti 1993 {published data only}
-
- Marchetti DL, Lele SB, Priore RL, McPhee ME, Hreshchyshyn MM. Treatment of Advanced Ovarian Carcinoma in the Elderly. Gynecologic Oncology 1993;49(1):86‐91. - PubMed
Ngan 1989 {published data only}
-
- Ngan HY, Choo YC, Cheung M, Wong LC, Ma HK, Collins R. A Randomized Study of High‐Dose versus Low‐Dose cis‐Platinum Combined with Cyclophosphamide in the Treatment of Advanced Ovarian Cancer. Chemotherapy 1989;35(3):221‐227. - PubMed
Omura 1989 {published data only}
-
- Omura GA, Bundy BN, Berek JS, Curry S, Delgado G Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 1989;7(4):457‐465. - PubMed
Palmer 1992 {published data only}
-
- Palmer MC, Shepert E, Schepansky A, MacLean GD. Novel, dose intensive, single‐agent cisplatin in the first‐line management of advanced stage ovarian cancer. International Journal of Gynecological Cancer 1992;2(6):301‐306. - PubMed
Piver 1991 {published data only}
-
- River MS, Fanning J, Sprance HE. Five‐year survival for cisplatin‐based chemotherapy versus single‐agent melphalan in patients with advanced ovarian cancer and optimal debulking surgery. Journal of Surgical Oncology 1991;48(1):39‐44. - PubMed
Redman 1986 {published data only}
-
- Redman JR, Petroni GR, Saigo PE, Geller NL, Hakes TB. Prognostic factors in advanced ovarian carcinoma. Journal of Clinical Oncology 1986;4(4):515‐523. - PubMed
Rose 2004 {published data only}
-
- Rose PG, Nerenstone S, Brady MF, Clarke‐Pearson D, Olt G, Rubin SC, et al and the Gynecologic Oncology Group. Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma. New England Journal of Medicine 2004;351(24):2489‐97. - PubMed
Sessa 1991 {published data only}
-
- Sessa C, Colombo N, Bolis G, Marsoni S, Mangioni C. Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long‐term results.. Cancer Treatment Reviews 1991;18(Mar;18 Suppl A):37‐46. - PubMed
Shapiro 1998 {published data only}
-
- Shapiro JD, Rothenberg ML, Sarosy, GA, Steinberg SM, Adamo DO, Reed E, et al. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. Cancer 1998;83(9):1980‐88. - PubMed
Shinozuka 1999 {published data only}
-
- Shinozuka T, Miyamoto T, Muramatsu T, Hirasawa T, Murakami M, Makino T, et al. High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: Long term results for 105 patients. Cancer 1999;85(7):1555‐64. - PubMed
Skarlos 1996 {published data only}
-
- Skarlos DV, Aravantinos G, Kosmidis P, Pavlidis N, Gennatas K, Beer M, et al. Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a hellenic co‐operative oncology group study. European Journal of Cancer 1996;32(3):421‐28. - PubMed
Strauss 1996 {published data only}
-
- Strauss G, Lund B, Hansen M, Hansen OP, Hansen HH. Combined high‐dose platinum and etoposide in previously untreated ovarian cancer patients with residual disease. International Journal of Gynecological Cancer 1996;6(5):410‐414.
Sun 2000 {published data only}
-
- Sun T, Feng Y, ZhuY, Zheng Y. Therapeutic strategy in the management of stage II ‐ IV epithelial ovarian carcinoma. Chinese Medical Journal 2000;113(7):625‐627. - PubMed
Sutton 1989 {published data only}
-
- Sutton GP, Stehman FB, Einhorn LH, Roth LM, Blessing JA, Ehrlich CE. Ten‐year follow‐up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. Journal of Clinical Oncology 1989;7:223‐229. - PubMed
Takano 2006 {published data only}
-
- Takano MJ, Kikuchi Y, Yaegashi N, Suzuki M, Tsuda H, Sagae S, et al. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncology Reports 2006;16(6):1301‐1306. - PubMed
Takano 2007 {published data only}
-
- Takano M, Sugiyama T, Yaegashi N, .Suzuki M, Sagae S, Udagawa, et al. Progression‐free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel‐carboplatin or irinotecan‐cisplatin: Retrospective analysis. International Journal of Clinical Oncology 2007;12(4):256‐260. - PubMed
Tay 1996 {published data only}
-
- Tay SK, Chang TC. An evaluation of the policy of routine treatment of advanced epithelial ovarian carcinoma by debulking surgery and combined platinum‐cyclophosphamide chemotherapy in Singapore. International Journal of Gynecological Cancer 1996;6(1):44‐48.
Taylor 1994 {published data only}
-
- Taylor AE, Wiltshaw E, Gore ME, Fryatt I, Fisher C. Long‐term follow‐up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. Journal Of Clinical Oncology 1994;12(10):2066‐70. - PubMed
Tingulstad 2003 {published data only}
-
- Tingulstad S, Skjeldestad FE, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstetrics and Gynecology 2003;102(3):499‐505. - PubMed
Todo 2003 {published data only}
-
- Todo Y, Sakuragi N, Oikawa M, Negishi H, Yamamoto R, Yoshiaki K, et al. Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma. International Journal of Clinical Oncology 2003;8(2):90‐96. - PubMed
Uyar 2005 {published data only}
-
- Uyar D, Frasure HE, Markman M, Gruenigen VE. Treatment patterns by decade of life in elderly women ([greater‐than or equal to]70 years of age) with ovarian cancer. Gynecologic Oncology 2005;98(3):403‐408. - PubMed
Vallejos 1997 {published data only}
-
- Vallejos C, Solidoro A, Castellano C, Barriga C, Galdos O, Casanova R, et al. Ifosfamide plus Cisplatin as Primary Chemotherapy of Advanced Ovarian Cancer. Gynecologic Oncology 1997;67(2):168‐171. - PubMed
Van Der Burg 1996 {published data only}
-
- Burg MEL, Lent M, Buyse M, Kobierska A, Maggioni A, Favalli G, et al. The role of intervention debulking surgery in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study. International Journal of Gynecological Cancer 1996;6:30‐38.
Vergote 2010 {published and unpublished data}
-
- Vergote I, Trope M, Claes G, Amant F, Kristensen GB, Ehlen T, et al. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. New England Journal of Medicine 2010;363(10):943‐53. - PubMed
Wadler 1996 {published data only}
-
- Wadler S, Yeap B, Vogl S, Carbone P. Randomized trial of initial therapy with melphalan versus cisplatin‐based combination chemotherapy in patients with advanced ovarian carcinoma: Initial and long term results ‐ Eastern Cooperative Oncology Group study E2878. Cancer 1996;77(4):733‐742. - PubMed
Warwick 1995 {published data only}
Willemse 1992 {published data only}
-
- Willemse PHB, Vries EGE, Kloppenburg M, Fontein DL, Aalders JG, Boonstra H, et al. Carboplatin with cyclophosphamide in patients with advanced ovarian cancer: an efficacy and quality‐adjusted survival analysis. International Journal of Gynecological Cancer 1992;2(5):236‐243. - PubMed
Wils 1990 {published data only}
-
- Wils JA. Long‐term follow‐up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center. Oncology 1990;47(2):115‐120. - PubMed
Wimberger 2007 {published data only}
-
- Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO‐OVAR). Gynecologic Oncology 2007;106(1):69‐74. - PubMed
Yamamoto 2007 {published data only}
-
- Yamamoto S, Tsuda H, Yoshikawa T, Kudoh K, Kita T, et al. Clear cell adenocarcinoma associated with clear cell adenofibromatous components: A subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics. American Journal of Surgical Pathology 2007;31(7):999‐1006. - PubMed
Zang 1999 {published data only}
-
- Zang RY, Zhang ZY, Cai SM, Li ZT, Chen J, et al. Cytoreductive surgery for stage IV epithelial ovarian cancer. Journal of Experimental & Clinical Cancer Research 1999;18(4):449‐54. - PubMed
Additional references
Armstrong, 2006
-
- Armstrong DK, Bundy BW, LariHuang HQ, Baergen RL, Shashikant C, Walker LJ, et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. New England Journal of Medicine 2006;354(1):34‐43. - PubMed
Benedet 2000
-
- Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers FIGO Committee on Gynecologic Oncology. International Journal of Gynaecology and Obstetrics 2000;70:209‐262. - PubMed
Bristow 2002
-
- Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta‐Analysis. Journal of Clinical Oncology 2002;20 (5):1248‐59. - PubMed
Chi 2007
-
- Chi DS, Ramirez PT, Teitcher JB, Mironov S, Sarasohn DM, Lyer RB. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. Journal of Clinical Oncology 2007;25:4946‐51. - PubMed
Colombo 2006
-
- Colombo N, Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I. Ovarian cancer. Critical Reviews in Oncology/Hematology 2006;60 (2):159‐179. - PubMed
Cotte 2010
Covens 2000
-
- Covens AL. A Critique of Surgical Cytoreduction in Advanced Ovarian Cancer. Gynecologic Oncology 2000;78:269‐74. - PubMed
Deeks 2001
-
- Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta‐Analysis in Context (2nd edition). London: BMJ Publication Group, 2001.
Deffieux 2006
-
- Deffieux X, Castaigne D, Pomel C. Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. International Journal of Gynecological Cancer 2006;16 (s1):35‐40. - PubMed
DerSimonian 1986
-
- DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88. - PubMed
Eisenkop 1998
-
- Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology 1998;69:103‐108. - PubMed
Eisenkop 2001
-
- Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction in ovarian cancer: is there a correlation with "biological aggressiveness" and survival?. Gynecolpogic Oncology 2001;82:435‐41. - PubMed
EUROCARE 2003
-
- Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, Grosclaude P, Hédelin G, Matsuda T, Møller H, Möller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D, and the EUROCARE Working Group. EUROCARE‐3: survival of cancer patients diagnosed 1990‐94 ‐ results and commentary. Annals of Oncology 2003;14 (Supplement 5):v61‐v118. - PubMed
Fader 2007
-
- Fader AN, Rose PG. Role of Surgery in Ovarian Carcinoma. Journal of Clinical Oncology 2007;25 (20):2873‐83. - PubMed
Girling 1996
-
- Girling JC, Soutter WP. Cytoreductive surgery in the primary management of advanced epithelial ovarian carcinoma: A topic for debate. International Journal of Gynecological Cancer 1996;1:81‐84.
GLOBOCAN 2002
-
- Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. 'Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. IARCPress, Lyon 2004.
Griffiths 1975
-
- Griffiths. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Journal of the National Cancer Institute Monographs 1975;42:1014. - PubMed
Higgins 2003
Hoskins 1994
-
- Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. 'The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial epithelial ovarian carcinoma: a Gynecologic Oncology Group study'. American Journal of Obstetrics and Gynecology 1994;170:974‐980. - PubMed
Hunter 1992
-
- Hunter RW, Alexander ND, Soutter WP. 'Meta‐analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis?'. American Journal of Obstetrics and Gynecology 1992;166:504‐511. - PubMed
IARC 2002
-
- Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents. IARC Scientific Publication No. 155,Lyon 2002; Vol. Volume VIII.
Jemal 2008
-
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics. CA: A Cancer Journal for Clinicians 2008;58:71‐96. - PubMed
Markman 2007
-
- Markman M. 'Concept of Optimal Surgical Cytoreduction in Advanced Ovarian Cancer: A Brief Critique and a Call for Action'. Journal of Clinical Oncology 2007;25 (27):4168‐70. - PubMed
Markman, 2001
-
- Markman M, Bundy BN, Alberts DS, Fowler JM, Clark‐Pearson DL, Carson LF, et al. Phase III Trial of Standard‐Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High‐Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small‐Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2001;19(4):1001‐07. - PubMed
McGuire 1996
-
- McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer. New England Journal of Medicine 1996;334(1):1‐6. - PubMed
Muggia, 2000
-
- Muggia FM, Braly PS, Brady MF, Sutton GN, Theodore HL, Samuel AL, et al. Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 2000;18(1):106‐115. - PubMed
Munstedt 2004
Ozols, 2003
-
- Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke‐Pearson DB, Mannel RA, et al. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 2003;21(17):3194‐3200. - PubMed
Parmar 1998
-
- Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Paulsen 2006
-
- Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short‐term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. International Journal of Gynecological Cancer 2006;16 (s1):11‐17. - PubMed
Quirk 2005
-
- Quirk JT, Natarajan N, Mettlin CJ. Age‐specific ovarian cancer incidence rate patterns in the United States. Gynecologic Oncology 2005;99(1):248‐250. - PubMed
Sharma 2005
-
- Sharma S, Driscoll DBA, Odunsi K, Venkatadri A, Lele S. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high‐risk surgical patients. American Journal of Obstetrics & Gynecology December 2005;193(6):2077‐82. - PubMed
Spriggs 2007
-
- Spriggs DR, Brady M, Vaccarello L, Clarke‐Pearson DL, Burger RA, Mannel R, et al. Phase III randomized trial of intravenous cisplatin plus a 24‐ or 96‐hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.. Journal of Clinical Oncology 2007;25(28):4466‐71. - PubMed
Stoeckle 2004
-
- Stoeckle E, Paravis P, Floquet A. 'Number of residual nodules, better than size, defines optimal surgery in advanced epithelial ovarian cancer'. International Journal of Gynecological Cancer 2004;14:779‐87. - PubMed
Sugarbaker 2009
-
- Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer. Current opinion in obstetrics and Gynecology 2009;21:15‐24. - PubMed
Trimbos 2003
-
- Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. 'Impact of adjuvant chemotherapy and surgical staging in early‐stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer ‐ Adjuvant Chemotherapy in Ovarian Neoplasm Trial'. Journal of the National Cancer Institute 2003;95:113‐25. - PubMed
Venesmaa 1992
-
- Venesmaa P, Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstetrics and Gynecology 1992;79:168‐172. - PubMed
Vergote 1998
-
- Vergote I, Wever I, Tjalma W, Gramberen M, Decloedt J, Dam P. Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 Patients. Gynecologic Oncology 1998;71 (3):431‐436. - PubMed
Vergote 2003
-
- Vergote I, Trimbos BJ. Treatment of patients with early epithelial ovarian cancer. Current Opinion in Oncology 2003;15 (6):452‐5. - PubMed
Von Georgi 2003
-
- Georgi R, Franke FE, Munstedt K. The influence of tumor biology, surgery, and postoperative therapy on patient prognosis in advanced ovarian carcinomas. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2003;111:189‐196. - PubMed
Zapardiel 2011
-
- Zapardiel I, Morrow CP. New terminology for cytoreduction in advanced ovarian cancer. The Lancet 2011;12:214. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous